Table 1.
Patient characteristics (ITT population)
| Baseline characteristics | Vandetanib 100 mg (n = 10) |
Vandetanib 300 mg (n = 12) |
|---|---|---|
| Median age, years (range) | 62.5 (38--77) | 61 (41--73) |
| Male (%) | 6 (60) | 5 (42) |
| Female (%) | 4 (40) | 7 (58) |
| Race | ||
| Caucasian (%) | 10 (100) | 12 (100) |
| WHO performance status (%) | ||
| 0 1 |
6 (60) 4 (40) |
8 (67) 4 (33) |
| Previous chemotherapy regimens (%) | ||
| Any | 10 (100) | 12 (100) |
| 1 | 1 (10) | 4 (33) |
| 2 | 3 (30) | 2 (17) |
| 3 or more | 6 (60) | 6 (50) |
| Prior cetuximab therapy (%) | 7 (70) | 7 (58) |
| Prior bevacizumab therapy (%) | 5 (50) | 4 (33) |